glp 1 and prostate cancer Glucagon-like peptide receptor agonists risk: advancing precision medicine through mechanistic understanding and clinical evidence | Biomarker Research The effect of GLP-1R agonists

Further dose increases: After at least 4 weeks on the current dose, the dosage may be increased in 2.5 mg increments

Both medications are TGA approved for the treatment of heart failure with preserved ejection fraction (HFpEF), but at the time of writing, neither is PBS subsidised for this indication (refer to the PBS schedule and TGA website for full details)

GLP-1 agonists are currently approved for three conditions: type 2 diabetes, obesity, and heart disease

Diabetologia (2013) 56:14136

Tirzepatide, a dual GIP/GLP-1 agonist, has demonstrated superior weight loss efficacy, reshaping prescriber preferences in obesity management